Literature DB >> 17046469

Varicella.

Ulrich Heininger1, Jane F Seward.   

Abstract

Varicella-zoster virus, a herpesvirus, causes varicella (chickenpox) and, after endogenous reactivation, herpes zoster (shingles). Varicella, which is recognised by a characteristic vesicular rash, arises mainly in young children, although older individuals can be affected. In immunocompetent patients, symptoms are usually mild to moderate, but an uncomplicated severe case can have more than 1000 lesions and severe constitutional symptoms. Serious complications--including central nervous system involvement, pneumonia, secondary bacterial infections, and death--are sometimes seen. Varicella can be prevented by vaccination. Vaccine is about 80-85% effective against all disease and highly (more than 95%) effective in prevention of severe disease. In the USA, a routine childhood immunisation programme has reduced disease incidence, complications, hospital admissions, and deaths in children and in the general population, indicating strong herd immunity. Similar immunisation programmes have been adopted by some other countries, including Uruguay, Germany, Taiwan, Canada, and Australia, and are expected to be implemented more widely in future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046469     DOI: 10.1016/S0140-6736(06)69561-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  155 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 2.  Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.

Authors:  Martina Prelog; Jörn Schönlaub; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-11-15       Impact factor: 3.714

Review 3.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Should the UK introduce varicella vaccine?

Authors:  Marion Roderick; Athimalaipet V Ramanan; Adam Finn
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

5.  Deterministic SIR (Susceptible-Infected-Removed) models applied to varicella outbreaks.

Authors:  J Ospina Giraldo; D Hincapié Palacio
Journal:  Epidemiol Infect       Date:  2007-07-26       Impact factor: 2.451

6.  Varicella pneumonia in an immunocompetent adult.

Authors:  Naveen Voore; Richard Lai
Journal:  CMAJ       Date:  2012-05-07       Impact factor: 8.262

7.  Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Authors:  Markus Knuf; Fred Zepp; Klaus Helm; Hartwig Maurer; Albrecht Prieler; Dorothee Kieninger-Baum; Martine Douha; Paul Willems
Journal:  Eur J Pediatr       Date:  2011-09-21       Impact factor: 3.183

Review 8.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

10.  Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy.

Authors:  Akinao Okamoto; Akihiro Abe; Masataka Okamoto; Tsukane Kobayashi; Tomohiko Terazawa; Yoko Inaguma; Masutaka Tokuda; Masamitsu Yanada; Satoko Morishima; Tadaharu Kanie; Yukiya Yamamoto; Motohiro Tsuzuki; Yoshiki Akatsuka; Shuichi Mizuta; Tetsushi Yoshikawa; Nobuhiko Emi
Journal:  Int J Hematol       Date:  2012-08-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.